Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA BIOMED WILL PRESENT
AT THE ICI EUROPE MEETING IN GERMANY,
NOVEMBER 16-18, 2015
SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced that
Dr. Fr d ric Triebel, Chief Scientific and Medical Officer, will be presenting at the forthcoming Immune Checkpoint Inhibitors Europe meeting (ICI Europe), to be held at Bad Homburg in Germany from 16 to 18 November.
ICI Europe, focused exclusively on checkpoint modulators, will see experts from a variety of established and emerging pharma companies discussing matters such
as clinically relevant biomarkers and preclinical models in immune-oncology, as well as combination strategies for clinical development. Dr. Triebel s presentation will take place during a segment looking at the discovery of novel immune
checkpoint pathways and will discuss LAG-3 as a next generation checkpoint. In his presentation Dr. Triebel will show some of the pre-clinical data generated for Prima s lead compound, IMP321, a first-in-class Antigen
Presenting Cell-Activator, as well as the Phase IIa data in metastatic breast cancer in conjunction with paclitaxel.
Event: Immune Checkpoint Inhibitors
Date: Wednesday 18 November 2015
p.m. (Central European Time)
Location: Maritim Hotel, Bad Homburg, Hesse, Germany
Prima BioMed is a globally active
biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of various types of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative
treatment options to market for patients and to maximise value to shareholders.
Prima s current lead product is IMP321, based on the LAG-3 immune
control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is a first-in-class Antigen Presenting Cell (APC) activator which has completed early Phase II trials. As
an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. A number of additional LAG-3 products including antibodies for immune response modulation in
autoimmunity and cancer are being developed by large pharmaceutical partners.
Prima BioMed Ltd, Level 12, 95 Pitt Street, Sydney NSW
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information
please visit www.primabiomed.com.au.
The presentation slides for this event will be made available for downloading from Prima s website
closer to the date of the event.
For further information please contact:
+61 (0) 447 247 909; stuart.roberts@primabiomed.com.au
Australia Investor/Media:
Mr Matthew Gregorowski,
+61 (0) 422 534 755; mgregorowski@citadelmagnus.com
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Level 12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889